Collegium Pharmaceutical (NASDAQ:COLL) Rating Reiterated by Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “hold” rating reiterated by analysts at Needham & Company LLC in a note issued to investors on Friday, Benzinga reports.

A number of other research analysts have also weighed in on the company. Piper Sandler lowered Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price on the stock. in a report on Friday, May 10th. HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Tuesday, July 30th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the company from $41.00 to $44.00 in a research report on Friday, June 7th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Collegium Pharmaceutical Stock Up 0.5 %

Shares of COLL stock traded up $0.18 on Friday, reaching $35.50. 413,104 shares of the company were exchanged, compared to its average volume of 471,066. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.21 and a quick ratio of 1.14. The company has a 50-day moving average of $33.09 and a 200-day moving average of $34.82. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 14.79 and a beta of 0.93. Collegium Pharmaceutical has a one year low of $20.95 and a one year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The firm had revenue of $144.92 million for the quarter, compared to analyst estimates of $147.04 million. Analysts anticipate that Collegium Pharmaceutical will post 5.73 earnings per share for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the transaction, the chief financial officer now owns 130,845 shares in the company, valued at approximately $4,476,207.45. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the transaction, the director now directly owns 44,775 shares in the company, valued at approximately $1,446,232.50. The disclosure for this sale can be found here. Insiders have sold a total of 105,502 shares of company stock worth $3,540,796 over the last 90 days. Corporate insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. New York State Teachers Retirement System raised its position in shares of Collegium Pharmaceutical by 23.2% in the 4th quarter. New York State Teachers Retirement System now owns 12,474 shares of the specialty pharmaceutical company’s stock worth $384,000 after acquiring an additional 2,350 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Collegium Pharmaceutical by 5.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,713 shares of the specialty pharmaceutical company’s stock valued at $514,000 after purchasing an additional 868 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Collegium Pharmaceutical by 10.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 45,862 shares of the specialty pharmaceutical company’s stock valued at $1,412,000 after buying an additional 4,192 shares during the last quarter. Louisiana State Employees Retirement System bought a new position in Collegium Pharmaceutical in the 4th quarter worth $502,000. Finally, Cornercap Investment Counsel Inc. raised its stake in shares of Collegium Pharmaceutical by 4.6% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 22,002 shares of the specialty pharmaceutical company’s stock worth $677,000 after buying an additional 959 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.